Document:

EX-10.12

 Exhibit 10.12 

UROVANT SCIENCES LTD. 

INDEMNITY AGREEMENT 

THIS INDEMNITY AGREEMENT (the “Agreement”) is made and
entered into as of                         , 20     between Urovant Science Ltd., an exempted
limited company registered in Bermuda (the “Company”), and                      (“Indemnitee”). 

RECITALS 

A.    Highly competent persons have become more reluctant to serve companies as directors or officers or in other
capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation; 

B.    Although furnishing of insurance to protect persons serving a company and its subsidiaries from certain
liabilities has been a customary and widespread practice among Bermuda companies and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at
higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to companies or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other
things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Bye-laws of the Company permit indemnification of the officers, directors and certain
other persons of the Company in accordance with Bermuda law; 
 C.    The uncertainties relating to such
liability insurance and to indemnification have increased the difficulty of attracting and retaining such persons; 

D.    The Board has determined that the increased difficulty in attracting and retaining such persons would be
detrimental to the best interests of the Company’s shareholders, and that the Company should act to assure such persons that there will be increased certainty of protection in the future; 

E.    It is reasonable, prudent, and necessary for the Company to contractually obligate itself to indemnify, and
to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; 

F.    This Agreement is a supplement to and in furtherance of the Company’s amended and restated Bye-laws (the “Bye-laws”) and any resolutions adopted pursuant to such indemnification, and will not be deemed a substitute therefor, nor to diminish or
abrogate any rights of Indemnitee; and 
 H.    Indemnitee may have certain rights to indemnification and
insurance provided by other entities or organizations which Indemnitee and such other entities and organizations intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided in this Agreement, with the
Company’s acknowledgment and agreement to the foregoing being a material condition to Indemnitee’s willingness to serve on the Board. 

I.    This Agreement supersedes and replaces in its entirety any previous indemnification agreement entered into
between the Company and the Indemnitee. 

  
 1. 

 NOW, THEREFORE, in consideration of
Indemnitee’s agreement to serve as an officer or a director from and after the date first written above, the parties agree as follows: 

1.    Indemnity of Indemnitee. The Company agrees to hold harmless and indemnify Indemnitee to the fullest
extent permitted by law, as such may be amended from time to time in accordance with the terms of this Agreement. In furtherance of this indemnification, and without limiting the generality of such indemnification: 

(a)    Proceedings Other Than Proceedings by or in the Right of the Company. Indemnitee will be entitled to
the rights of indemnification provided in this Section 1(a) if, by reason of his or her Corporate Status, the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding other than a Proceeding by or in the right of
the Company. Pursuant to this Section 1(a), Indemnitee will be indemnified against all Expenses, judgments, penalties, fines, and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her behalf, in connection
with such Proceeding or any claim, issue, or matter. This indemnification is provided if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with
respect to any criminal Proceeding, had no reasonable cause to believe the Indemnitee’s conduct was fraudulent or dishonest to the extent prohibited by the Companies Act of 1981 of Bermuda, as amended. 

(b)    Proceedings by or in the Right of the Company. Indemnitee will be entitled to the rights of
indemnification provided in this Section 1(b) if, by reason of his or her Corporate Status, the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company. Pursuant to this
Section 1(b), Indemnitee will be indemnified against all Expenses actually and reasonably incurred by the Indemnitee, or on the Indemnitee’s behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner
the Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Company. Indemnification will not be provided against such Expenses if made in respect of any claim, issue, or matter in such Proceeding as to which Indemnitee
will have been adjudged to be liable to the Company unless and to the extent that a court of competent jurisdiction will determine that such indemnification may be made. 

(c)    Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other
provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he or she will be indemnified to the maximum extent permitted by
law against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but
less than all claims, issues or matters in such Proceeding, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue,
or matter. For purposes of this Section, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, will be deemed to be a successful result as to such claim, issue, or matter. 

2.    Additional Indemnity. In addition to, and without regard to any limitations on, the indemnification
provided for in Section 1, the Company agrees to indemnify and hold Indemnitee harmless against all Expenses, judgments, penalties, fines, and amounts paid in settlement actually and reasonably incurred by him or her or on his or her behalf if,
by reason of his or her Corporate Status, he or she is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, any and all liability arising
out of the negligence or active or passive wrongdoing of Indemnitee. The only limitation that will exist on the Company’s obligations pursuant to this Agreement will be that the Company will not be obligated to make any payment to Indemnitee
that is finally determined (under the procedures, and subject to the presumptions, in Sections 6 and 7) to be unlawful. 

  
 2. 

 3.    Contribution. 

(a)    Whether or not the indemnification provided in Sections 1 and 2 is available, in respect of any threatened,
pending, or completed action, suit, or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit, or proceeding), the Company will pay, in the first instance, the entire amount of any judgment or
settlement of such action, suit, or proceeding without requiring Indemnitee to contribute to such payment, and the Company waives and relinquishes any right of contribution it may have against Indemnitee. The Company will not enter into any
settlement of any action, suit, or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit, or proceeding) unless such settlement provides for a full and final release of all claims asserted
against Indemnitee. The Company will not settle any action or claim in a manner that would impose any penalty or admission of guilt or liability on Indemnitee without Indemnitee’s written consent. 

(b)    Without diminishing or impairing the obligations of the Company in the preceding subparagraph, if Indemnitee
elects or is required to pay all or any portion of any judgment or settlement in any threatened, pending, or completed action, suit, or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit, or
proceeding), the Company will contribute to the amount of Expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company
and all officers, directors, or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit, or proceeding), on the one hand, and Indemnitee, on the other hand, from the
transaction from which such action, suit or proceeding arose. To the extent necessary to conform to law, the proportion determined on the basis of relative benefit may be further adjusted by reference to the relative fault of the Company and all
officers, directors, or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the
events that resulted in such expenses, judgments, fines, or settlement amounts, as well as any other equitable considerations which the applicable law may require to be considered. The relative fault of the Company and all officers, directors, or
employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, will be determined by reference to, among other
things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary, and the degree to which their respective conduct is active or passive. 

(c)    The Company agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may
be brought by the Company’s officers, directors, or employees, other than Indemnitee, who may be jointly liable with Indemnitee. 

(d)    To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement
is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, will contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in
settlement or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding to reflect: (i) the
relative benefits received by the Company and Indemnitee as a result of the events and transactions giving cause to such Proceeding; and (ii) the relative fault of the Company (and its directors, officers, employees, and agents) and Indemnitee
in connection with such events and transactions. 

  
 3. 

 4.    Indemnification for Expenses of a Witness.
Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not a
party, he or she will be indemnified against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. 

5.    Advancement of Expenses. Notwithstanding any other provision of this Agreement, the Company will
advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee’s Corporate Status within 30 days after the receipt by the Company of a statement from Indemnitee requesting such advance or
advances, whether prior to or after final disposition of such Proceeding. Such statement will reasonably evidence the Expenses incurred by Indemnitee and will include or be preceded or accompanied by a written undertaking by or on behalf of
Indemnitee to repay any Expenses advanced if it is ultimately determined that Indemnitee is not entitled to be indemnified against such Expenses. Any advances and undertakings to repay pursuant to this Section 5 will be unsecured and interest
free. 
 6.    Procedures and Presumptions for Determination of Entitlement to Indemnification. It is the
intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under Bermuda law. Accordingly, the parties agree that the following procedures and presumptions will apply in the event of any question
as to whether Indemnitee is entitled to indemnification under this Agreement: 
 (a)    To obtain indemnification
under this Agreement, Indemnitee will submit to the Company a written request with such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled
to indemnification. The Secretary of the Company will, promptly on receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to
provide such request to the Company, or to provide such a request in a timely fashion, will not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the
interests of the Company. 
 (b)    On written request by Indemnitee for indemnification pursuant to the first
sentence of Section 6(a), Indemnitee’s entitlement to indemnification will be determined in the specific case: 
 (1) by one of the
following three methods, which will be at the election of the Board: 
 (i)    by a majority vote of the Disinterested
Directors, even though less than a quorum; 
 (ii) by a committee of Disinterested Directors designated by a majority vote of the
Disinterested Directors, even though less than a quorum; or 
 (iv) if so directed by the Board, by the shareholders of the Company; or 

(c)    In making a determination with respect to entitlement to indemnification under this Agreement, the person or
persons or entity making such determination will presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption will 

  
 4. 

 
have the burden of proof and the burden of persuasion by clear and convincing evidence. Neither the failure of the Company (including by its Board) to have made a determination prior to the
commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its Board) that
Indemnitee has not met such applicable standard of conduct, will be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. 

(d)    Indemnitee will be deemed to have acted in good faith if Indemnitee’s action is based on the records or
books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or
records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and actions, or failure to act, of any
director, officer, agent, or employee of the Enterprise will not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 6(e) are satisfied,
it will in any event be presumed that Indemnitee has at all times acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Company. Anyone seeking to overcome this presumption will have
the burden of proof and the burden of persuasion by clear and convincing evidence. 
 (e)    If the person,
persons, or entity empowered or selected under Section 6 to determine whether Indemnitee is entitled to indemnification has not have made a determination within 60 days after receipt by the Company of the request, the requisite determination of
entitlement to indemnification will be deemed to have been made, and Indemnitee will be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material fact or an omission of a material fact necessary to make
Indemnitee’s statement not materially misleading in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. Such 60-day period may be
extended for a reasonable time, not to exceed an additional 30 days, if the person, persons, or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate
documentation or information relating thereto. The provisions of this Section 6(f) will not apply if the determination of entitlement to indemnification is to be made by the shareholders pursuant to Section 6(b) and if (A) within 15
days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such determination to the shareholders for their consideration at an annual meeting to be held
within 75 days after such receipt, and such determination is made at that annual meeting, or (B) a special meeting of shareholder is called within 15 days after such receipt for the purpose of making such determination, such meeting is held for
such purpose within 60 days after having been so called and such determination is made at that special meeting. 

(f)    Indemnitee will cooperate with the person, persons, or entity making such determination with respect to
Indemnitee’s entitlement to indemnification, including providing such person, persons, or entity on reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is
reasonably available to Indemnitee and reasonably necessary to such determination. Any member of the Board, or shareholder of the Company will act reasonably and in good faith in making a determination regarding the Indemnitee’s entitlement to
indemnification under this Agreement. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons, or entity making such determination will be borne by the Company
(irrespective of the determination as to Indemnitee’s entitlement to indemnification), and the Company indemnifies and agrees to hold Indemnitee harmless therefrom. 

  
 5. 

 (g)    The Company acknowledges that a settlement or other disposition
short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption, and uncertainty. In the event that any action, claim, or proceeding to which Indemnitee is a party is resolved in any manner other than
by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it will be presumed that Indemnitee has been successful on the merits or
otherwise in such action, suit, or proceeding. Anyone seeking to overcome this presumption will have the burden of proof and the burden of persuasion by clear and convincing evidence. 

(h)    The termination of any Proceeding or of any claim, issue, or matter in any Proceeding, by judgment, order,
settlement or conviction, or on a plea of nolo contendere or its equivalent, will not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that
Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that
his or her conduct was unlawful. 
 7.    Remedies of Indemnitee. 

(a)    In the event that (i) a determination is made pursuant to Section 6 that Indemnitee is not entitled
to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 5, (iii) subject to the limitations set forth herein, no determination of entitlement to indemnification is made pursuant to
Section 6(b) within 90 days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to this Agreement within 10 days after receipt by the Company of a written request for such
payment, or (v) payment of indemnification is not made within 10 days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Section 6, Indemnitee
will be entitled to an adjudication in an appropriate court in Bermuda or in any other court of competent jurisdiction, of Indemnitee’s entitlement to such indemnification. Indemnitee will commence such proceeding seeking an adjudication within
one year following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 7(a). The Company will not oppose Indemnitee’s right to seek any such adjudication. 

(b)    In the event that a determination has been made pursuant to Section 6(b) that Indemnitee is not entitled
to indemnification, any judicial proceeding commenced pursuant to this Section 7 will be conducted in all respects as a de novo trial on the merits, and Indemnitee will not be prejudiced by reason of the adverse determination under
Section 6(b). 
 (c)    If a determination has been made pursuant to Section 6(b) that Indemnitee is
entitled to indemnification, the Company will be bound by such determination in any judicial proceeding commenced pursuant to this Section 7, absent (i) a misstatement by Indemnitee of a material fact or an omission of a material fact
necessary to make Indemnitee’s misstatement not materially misleading in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law. 

(d)    In the event that Indemnitee, pursuant to this Section 7, seeks a judicial adjudication of his or her
rights under, or to recover damages for breach of, this Agreement, or to recover under any directors’ and officers’ liability insurance policies maintained by the Company, the Company will pay on his or her behalf, in advance, any and all
expenses (of the types described in the definition of Expenses) actually and reasonably incurred by him or her in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification,
advancement of expenses, or insurance recovery. 

  
 6. 

 (e)    The Company will be precluded from asserting in any judicial
proceeding commenced pursuant to this Section 7 that the procedures and presumptions of this Agreement are not valid, binding, and enforceable, and will stipulate in any such court that the Company is bound by all the provisions of this
Agreement. The Company will indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, will (within 10 days after receipt by the Company of a written request therefore) advance, to the extent not prohibited by law, such
expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability
insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses, or insurance recovery, as the case may be. 

(f)    Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to
indemnification under this Agreement will be required to be made prior to the final disposition of the Proceeding. 

8.    Non-Exclusivity; Survival of Rights; Insurance; Primacy of
Indemnification; Subrogation. 
 (a)    The rights of indemnification as provided by this Agreement will not
be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Bye-laws, any agreement, a vote of shareholders, a resolution of Board, or otherwise. No
amendment, alteration, or repeal of this Agreement or of any provision of this Agreement will limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status
prior to such amendment, alteration, or repeal. To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the
Bye-laws, and this Agreement, it is the intent of the parties of this Agreement that Indemnitee will enjoy all greater benefits so afforded by such change. No right or remedy in this Agreement conferred is
intended to be exclusive of any other right or remedy, and every other right and remedy will be cumulative and in addition to every other right and remedy given under this Agreement or now or hereafter existing at law or in equity or otherwise. The
assertion or employment of any right or remedy under this Agreement, or otherwise, will not prevent the concurrent assertion or employment of any other right or remedy. 

(b)    To the extent that the Company maintains an insurance policy or policies providing liability insurance for
directors, officers, employees, or agents, or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan, or other enterprise that such person serves at the request of the Company, the Company
will procure such insurance policy or policies under which the Indemnitee will be covered in accordance with its or their terms to the maximum extent of the coverage available for any director, officer, employee, agent, or fiduciary under such
policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms of this Agreement, the Company has director and officer liability insurance in effect, the Company will give prompt notice of the commencement of such
proceeding to the insurers in accordance with the procedures in the respective policies. The Company will thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result
of such proceeding in accordance with the terms of such policies. 
 (c)    The Company acknowledges that
Indemnitee has or may have in the future certain rights to indemnification, advancement of expenses, or insurance provided by other entities or 

  
 7. 

 
organizations (collectively, the “Secondary Indemnitors”). The Company agrees that (i) it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary
and any obligation of the Secondary Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) it will be required to advance the full amount of expenses incurred by
Indemnitee and will be liable for the full amount of all Expenses, judgments, penalties, fines, and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement, the Company’s Bye-laws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Secondary Indemnitors, and (iii) it irrevocably waives, relinquishes, and
releases the Secondary Indemnitors from any and all claims against the Secondary Indemnitors for contribution, subrogation, or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the
Secondary Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company will affect the foregoing and the Secondary Indemnitors will have a right of contribution and be subrogated to
the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Secondary Indemnitors are express third party beneficiaries of the terms of this
Section 8(c). 
 (d)    Except as provided in Section 8(c), in the event of any payment under this
Agreement, the Company will be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee (other than against the Secondary Indemnitors), who will execute all papers required and take all action necessary to secure such
rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. 

(e)    Except as provided in Section 8(c), the Company will not be liable under this Agreement to make any
payment of amounts otherwise indemnifiable under this Agreement if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement, or otherwise. 

(f)    Except as provided in Section 8(c), the Company’s obligation to indemnify or advance Expenses under
this Agreement to Indemnitee who is or was serving at the request of the Company as a director, officer, employee, or agent of any other corporation, partnership, joint venture, trust, employee benefit plan, or other enterprise will be reduced by
any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan, or other enterprise. 

9.    Exceptions to Right of Indemnification. Notwithstanding any provision in this Agreement, the Company
will not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee: 

(a)    for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other
indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision, provided that the foregoing will not affect the rights of Indemnitee or the Secondary Indemnitors in
Section 8(c); 
 (b)    for an accounting of profits made from the purchase and sale (or sale and purchase)
by Indemnitee of shares of the Company; 
 (c)    in connection with any Proceeding (or any part of any
Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, or other indemnitees, unless (i) the Board authorized the
Proceeding (or any part of any Proceeding) prior to its initiation, or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; 

  
 8. 

 (d)    with respect to remuneration paid to Indemnitee if it is
determined by final judgment or other final adjudication that such remuneration was in violation of law; 

(e)     a final judgment or other final adjudication is made that Indemnitee’s conduct was fraudulent or
dishonest (but only to the extent of such specific determination); 
 (f)    in connection with any claim for
reimbursement or any recovery policy of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of shares of the Company, as required in each case under the
Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act or Section 954 of the Dodd-Frank Act, or the payment to the Company of profits
arising from the purchase and sale by Indemnitee of shares or securities in violation of Section 306 of the Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement); or 

(g)    on account of conduct that is established by a final judgment as constituting a breach of Indemnitee’s
duty of loyalty to the Company or resulting in any personal profit or advantage to which Indemnitee is not legally entitled. 
 For purposes
of this Section 9, a final judgment or other adjudication may be reached in either the underlying proceeding or action in connection with which indemnification is sought or a separate proceeding or action to establish rights and liabilities
under this Agreement. 
 Any provision herein to the contrary notwithstanding, the Company will not be obligated pursuant to the terms of
this Agreement to indemnify Indemnitee or otherwise act in violation of any undertaking appearing in and required by the rules and regulations promulgated under the Securities Act, or in any registration statement filed with the SEC under the
Securities Act. Indemnitee acknowledges that paragraph (h) of Item 512 of Regulation S-K promulgated under the Securities Act currently generally requires the Company to undertake, in connection with any
registration statement filed under the Securities Act, to submit the issue of the enforceability of Indemnitee’s rights under this Agreement in connection with any liability under the Securities Act on public policy grounds to a court of
appropriate jurisdiction and to be governed by any final adjudication of such issue. Indemnitee specifically agrees that any such undertaking will supersede the provisions of this Agreement and to be bound by any such undertaking. 

10.    Duration of Agreement. All agreements and obligations of the Company contained herein will continue
during the period Indemnitee is an officer or director of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and
will continue thereafter so long as Indemnitee will be subject to any Proceeding (or any proceeding commenced under Section 7) by reason of his or her Corporate Status, whether or not he or she is acting or serving in any such capacity at the
time any liability or expense is incurred for which indemnification can be provided under this Agreement. This Agreement will be binding on and inure to the benefit of and be enforceable by the parties of this Agreement and their respective
successors (including any direct or indirect successor by purchase, merger, consolidation, or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors, and personal and legal
representatives. 

  
 9. 

 11.    Security. To the extent requested by Indemnitee and
approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company’s obligations under this Agreement through an irrevocable bank line of credit, funded trust, or other collateral. Any such
security, once provided to Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee. 

12.    Enforcement. 

(a)    The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations
imposed on it to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying on this Agreement in serving as an officer or director of the Company. 

(b)    Other than as provided in this Agreement, this Agreement constitutes the entire agreement between the parties
with respect to this subject matter and supersedes all prior agreements and understandings, oral, written and implied, between the parties with respect to this subject matter. 

13.    Definitions. For purposes of this Agreement: 

(a)    “Beneficial Owner” has the meaning given to such term in Rule
13d-3 under the Exchange Act; provided that Beneficial Owner will exclude any Person otherwise becoming a Beneficial Owner by reason of the shareholders of the Company approving a merger of the Company
with another entity. 
 (b)    “Board” means the Board of Directors of the Company. 

(c)    “Change in Control” means the earliest to occur after the date of this Agreement of any of
the following events: 
 (i)    Acquisition of Securities by Third Party. Any Person is or becomes the
Beneficial Owner (as defined above), directly or indirectly, of shares of the Company representing twenty five percent (25%) or more of the combined voting power of the Company’s then outstanding shares; 

(ii)    Change in Board. During any period of two (2) consecutive years (not including any period prior
to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction
described in clause (i), (iii) or (iv) of this definition of Change in Control) whose election by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least
two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to
constitute a majority of the members of the Board; 
 (iii)    Corporate Transactions. The effective date
of a merger, amalgamation or consolidation of the Company with any other entity, other than a merger, amalgamation or consolidation which would result in the voting shares of the Company outstanding immediately prior to such merger, amalgamation or
consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 51% of the combined voting power of the voting shares of the surviving or amalgamated entity
outstanding immediately after such merger, amalgamation or consolidation and with the power to elect a majority of the Board or other governing body of such surviving or amalgamated entity; 

  
 10. 

 (iv)    Liquidation. The approval by the shareholders of the
Company of a complete liquidation and winding-up of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and 

(v)    Other Events. There occurs any other event of a nature that would be required to be reported in
response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject to such reporting requirement. 

(d)    “Corporate Status” describes the status of a person who is or was a director, officer,
employee, agent or fiduciary of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the express written request of the Company. 

(e)    “Disinterested Director” means a non-executive
director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee. 

(f)    “Dodd-Frank Act” means the Dodd-Frank Wall Street Reform and Consumer Protection Act of
2010. 
 (g)    “Enterprise” means the Company and any other corporation, partnership, joint
venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary. 

(h)    “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(i)    “Expenses” includes all documented and reasonable attorneys’ fees, retainers, court
costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in
connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding.
Expenses also will include Expenses incurred in connection with any appeal resulting from any Proceeding and any federal, state, local, or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this
Agreement, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent. Expenses will not include amounts paid in settlement by Indemnitee or the amount
of judgments or fines against Indemnitee. 
 (j)     “Person” for purposes of the definition of
Beneficial Owner and Change in Control set forth above, will have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided that Person will exclude (i) the Company, (ii) any trustee or other fiduciary
holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of shares of the Company.

 (k)    “Proceeding” includes any threatened, pending or completed action, suit, arbitration,
alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal,
administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise, by reason of the fact that Indemnitee is or was an officer or director of the Company, by reason of any action taken by him or her or of any
inaction on his or her part while 

  
 11. 

 
acting as an officer or director of the Company, or by reason of the fact that he or she is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary of
another corporation, partnership, joint venture, trust or other Enterprise; in each case whether or not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided
under this Agreement; including one pending on or before the date of this Agreement, but excluding one initiated by an Indemnitee pursuant to Section 7 of this Agreement to enforce his or her rights under this Agreement. 

(l)    “Sarbanes-Oxley Act” will mean the Sarbanes-Oxley Act of 2002, as amended. 

(m)    “SEC” will mean the Securities and Exchange Commission. 

(n)    “Securities Act” will mean the Securities Act of 1933, as amended. 

14.    Severability. The invalidity or unenforceability of any provision hereof will in no way affect the
validity or enforceability of any other provision. Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws. In the event any
provision hereof conflicts with any applicable law, such provision will be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict. 

15.    Modification and Waiver. No supplement, modification, termination or amendment of this Agreement will
be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement will be deemed or will constitute a waiver of any other provisions hereof (whether or not similar) nor will such waiver
constitute a continuing waiver. 
 16.    Notice By Indemnitee. Indemnitee agrees promptly to notify the
Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered under this
Agreement. The failure to so notify the Company will not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the
Company. 
 17.    Notices. All notices and other communications given or made pursuant to this Agreement
will be in writing and will be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so
confirmed, then on the next business day, (c) 5 days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt. All communications will be sent: 
  

	 	(a)	 To Indemnitee at the address on the books and records of the Company. 

 

	 	(b)	 To the Company at: 

Urovant Sciences, Inc. 

Attention: General Counsel 

5151 California Avenue, Suite 250 

Irvine, California 92617 
 or to such other
address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be. 

  
 12. 

 18.    Counterparts. This Agreement may be executed in two or
more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature, electronic mail (including .pdf or any
electronic signature complying with the U.S. Federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and in two or more counterparts, each of which will be deemed an original, but all of which together will constitute
one and the same instrument and be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

19.    Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and will
not be deemed to constitute part of this Agreement or to affect the construction thereof. 
 20.    Governing
Law and Consent to Jurisdiction. This Agreement, and all rights, remedies, liabilities, powers and duties of the parties of this Agreement, shall be governed by and construed in accordance with the laws of Bermuda without regard to its
principles of conflicts of laws. 
 [Signature page follows.] 

  
 13. 

 IN WITNESS WHEREOF, the
parties hereto have entered into this Agreement effective as of the date first above written. 
  

					
	UROVANT SCIENCES LTD.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

  

	
	INDEMNITEE
	
	   

	Signature of Indemnitee
	
	   

	Print or Type Name of Indemnitee

  
 [Signature page to
Urovant Sciences, Inc. Indemnity Agreement]EX-10.16

 Exhibit 10.16 

UROVANT SCIENCES, INC. 

EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”) is entered into as of September 14, 2017, by and between Keith
Katkin (the “Executive”) and Urovant Sciences, Inc. (the “Company”). 

RECITALS 

A. The Company desires the association and services of the Executive and his skills, abilities, background and knowledge, and is
willing to engage the Executive’s services on the terms and conditions set forth in this Agreement. 
 B. The Executive desires
to be in the employ of the Company, and is willing to accept such employment on the terms and conditions set forth in this Agreement. 

C. This Agreement supersedes any and all prior and contemporaneous oral or written employment agreements or arrangements between the
Executive and the Company or any predecessor thereof. 
 AGREEMENT 

In consideration of the foregoing, the parties agree as follows: 

1. EMPLOYMENT BY THE COMPANY. 

1.1 Position; Duties. Subject to the terms and conditions of this Agreement, the Executive shall hold the position of President
and Chief Executive Officer of the Company. In this position, the Executive will have the duties and authorities normally associated with a chief executive officer of a company. The Executive will report to, and be subject to the direction of, the
Board of Directors of the Company (the “Board”). The Executive shall devote the Executive’s full business energies, interest, abilities and productive time to the proper and efficient performance of the Executive’s
duties under this Agreement; provided, however, that the Executive may devote reasonable periods of time to (a) serving on the board of directors of other corporations subject to the prior approval of the Board, and
(b) engaging in charitable or community service activities, so long as none of the foregoing additional activities materially interfere with the Executive’s duties under this Agreement. 

1.2 Service to Affiliates. It is understood and agreed that the Executive’s duties may include providing services to or for
the benefit of the Company’s affiliates, including, but not limited to, Urovant Sciences, Ltd. (the “Parent”), provided, that the Executive agrees that he will not provide any services from within the United States for
the Parent or any affiliate or subsidiary of the Parent that is organized in a jurisdiction outside the United States. In addition, at such time as when the Parent files a registration statement registering an offering of securities under the
Securities Act of 1933, the Executive shall become the Principal Executive Officer of the Parent solely for the requirements of the Parent being a registrant with the Securities and Exchange Commission. The Executive will also serve as a member of
the Parent’s board of directors (the “Parent Board”) and as a member of the board of directors of Urovant Sciences GmbH, an affiliate 

  
 1. 

 
of the Company. The Executive will not become an employee of the Parent, and the Executive’s activities as a Principal Executive Officer of the Parent shall be strictly ministerial and shall
not involve conducting any of the Parent’s business activities from within the United States, including day-to-day management or other operational activities of the
Parent. 
 1.3 Location of Employment. The Executive’s principal location of employment shall be the Company’s
principal base of operations, which is currently expected to be in Orange County, California, or within fifty (50) miles thereof. The Executive understands that his duties may require periodic business travel, including, for the avoidance of
doubt, his required part-time presence in New York, New York during the initial ramp up period of employment that is expected to continue for approximately three (3) months from the Start Date. 

1.4 Policies and Procedures. The employment relationship between the parties shall be governed by this Agreement and by the
written employment policies and practices established by the Company and/or its Board, to the extent provided to the Executive in advance of the application thereof to the Executive. In the event that the terms of this Agreement differ from or are
in conflict with the Company’s policies or practices, this Agreement shall govern and control. 
 1.5 Exclusive Employment;
Agreement not to Participate in Company’s Competitors. Subject to Section 1.1 and 1.2 above, except with the prior written consent of the Board, the Executive will not during his employment with the Company undertake or engage in any
other employment, occupation or business enterprise. During the Executive’s employment, the Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Executive to be
adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person, or entity that is, directly or indirectly, in competition with the business of the Company. Ownership by the Executive in
professionally managed funds over which the Executive does not have control or discretion in investment decisions, or, an investment of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes
of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute
a breach of this Section. 
 1.6 Start Date. The Executive’s employment with the Company shall commence on
September 21, 2017 (the “Start Date”). 
 2.
AT-WILL EMPLOYMENT. 
 The Executive’s
employment relationship with the Company is, and shall at all times remain, at-will. This means that either the Executive or the Company may terminate the employment relationship at any time, for any reason or
for no reason, with or without Cause (as defined below) or advance notice; provided, however, however, the Executive must provide the Company at least three (3) months’ advance written notice of the Executive’s intention
to resign from employment (except for a resignation for Good Reason, in which case such procedure shall be governed by the terms set forth in the definition of Good Reason) and the Company shall provide the Executive written notice in the event of a
termination of the Executive’s employment by the Company without Cause. 

  
 2. 

 3. COMPENSATION AND BENEFITS. 

3.1 Salary. The Company shall pay the Executive a base salary at the annualized rate of $300,000.00 (the “Base
Salary”), less payroll deductions and all required withholdings, payable in regular periodic payments in accordance with the Company’s normal payroll practices. The Base Salary shall be prorated for any partial year of employment
on the basis of a 365-day year. The Base Salary shall be subject to periodic review and may be adjusted from time to time in the Board’s discretion in consultation with the Executive and in consideration
of peer compensation data, to the extent available, including other affiliates of RSL. 
 3.2 Annual Performance Bonus. Each
fiscal year, the Executive will be eligible to earn an annual discretionary cash bonus (the “Annual Performance Bonus”) with a target bonus opportunity equal to 150% of the Executive’s Base Salary, based on the
Board’s assessment of the Executive’s individual performance and overall Company performance. In order to earn and receive the Annual Performance Bonus, the Executive must remain employed by the Company through and including the last day
of the applicable fiscal year, which will be on March 31 st of the year following the year for which the Annual Performance Bonus relates. The Annual Performance Bonus, if any, will be paid no later than thirty (30) days following the end
of the Company’s fiscal year or by April 30th. The Annual Performance Bonus payable, if any, shall be prorated if the Company’s review or assessment of the Executive’s performance covers a period that is less than a full fiscal year.
The foregoing to the contrary notwithstanding, with respect to fiscal year 2017, ending on March 31, 2018, the Executive shall be eligible to receive a guaranteed Annual Performance Bonus of $300,000, provided the Executive remains employed by
the Company through March 31, 2018. The determination of whether the Executive has earned a bonus and the amount thereof shall be determined by the Board (and/or a committee thereof) in its sole discretion. The Board (and/or a committee
thereof) reserves the right to modify the bonus criteria from year to year. 
 3.3 Equity. 

(a) On the Start Date, subject to the terms of the Parent’s 2017 Equity Incentive Plan (the “Plan”) and
approval of the grant by the Parent Board, the Executive will be granted an option to purchase 3,750,000 shares of Parent common stock (the “Time-Vesting Options”), which shall vest and become exercisable in accordance with
this Section 3.3(a). In addition, on the Start Date, the Executive will be granted an additional option to purchase up to 750,000 shares of Parent common stock (the “Anti-Dilution Options”, and together with the
Time-Vesting Options, the “Option Awards”), which shall only be eligible to vest and become exercisable under the circumstances set forth below under Section 3.3(c). The Time Vesting Options will represent 5% of the
basic Parent common shares outstanding as of the Start Date. Both the Time-Vesting Options and the Anti-Dilution Options under each Option Award will have an exercise price equal to the fair market value of the common stock on the grant date and
will, subject to Section 3.3(c) below, be subject to a 4-year vesting period, with (i) twenty-five percent (25%) of each Option Award vesting on the one-year
anniversary of the Start Date and (ii) the balance of the Option Awards vesting in a series of twelve (12) successive equal quarterly installments measured from the first anniversary of the Start Date, provided the Executive is employed by
the Company on each such vesting date. The Option Awards will be governed by the Plan and other documents issued in connection with the grants and will expire and cease to be 

  
 3. 

 
exercisable on the ten (10) year anniversary of the Start Date. Upon a Change of Control (as defined in the Plan), any unvested portion of the Option Awards (except the portion of the
Anti-Dilution Options that have not satisfied the dilution performance condition set forth in Section 3.3(c)) shall immediately vest in full. 

(b) The Executive shall also receive a grant of 66,845 restricted stock units in Roivant Sciences Ltd.
(“RSL”), an affiliate of the Company (the “RSL Grant”). The RSL Grant will be subject to the terms of the Roivant Sciences Ltd. 2015 Restricted Stock Unit Plan (the “RSL RSU
Plan”) and the applicable award agreement. The terms of the RSL Grant shall be identical to the terms of grants made to RSL and Roivant Sciences Inc. senior management team members participating in the RSL RSU Plan. The RSL Grant is
subject to approval by the board of directors of RSL. 
 (c) The Time-Vesting Options shall vest and become exercisable in
accordance with the conditions set forth in Section 3(a). Until such point that the Company cumulatively raises an aggregate of two hundred million ($200,000,000) in capital (including capital contributions from RSL or otherwise), the
Anti-Dilution Options shall, at such times as new common shares of the Parent should be issued (subject further to the time-vesting conditions set forth in Section 3(a) above), become vested in a portion of the Anti-Dilution Options equal to
five percent (5%) of the total Parent common shares issued and outstanding in excess of 75,000,000 Parent common shares (excluding any common shares that become issued and outstanding through the exercise or vesting of outstanding equity awards
after the date hereof). For the avoidance of doubt, the portion of the Anti-Dilution Options which have not satisfied their performance-vesting dilution condition at such time when the Parent has raised an aggregate of $200 million from any
source shall be forfeited. In the event that Parent issues more than an aggregate of 15,000,000 shares of common stock (excluding any common shares that become issued and outstanding through the exercise or vesting of outstanding equity awards after
the date hereof) (the “Share Cap”) before the Parent has raised an aggregate of $200 million from any source, then the Executive shall receive one or more additional option grants (“Anti-Dilution
Grants”) equal to five (5%) of the excess amount over the Share Cap. Any such additional Anti-Dilution Grants will have an exercise price equal to the fair market value of the Parent common shares at the time of grant and have vesting
terms, measured from the grant date rather than the Start Date, that are similar to the Time-Vesting Options. The Anti-Dilution Grants will be governed by the Plan and other documents issued in connection with the grants. 

Example #1: If the Parent issues 1,000,000 shares in excess of 75,000,000 common shares for consideration not to exceed
$200 million of proceeds on the sixth (6th) month anniversary of the Start Date, then five percent (5%) of such 1,000,000 shares (or 50,000 shares) will be eligible for vesting in accordance with Section 3.3(a). Accordingly, 12,500 of
these “performance vested” common shares will vest on the one (1) year anniversary of the Start Date, with the remaining 37,500 shares vesting quarterly over the next three (3) years, subject to the Executive’s continued
employment on each vesting date. 
 Example #2: If the Parent issues 3,000,000 shares of common stock in excess of 75,000,000 for
consideration not to exceed $200 million of proceeds on the two (2) year anniversary of the Start Date, then five percent (5%) of such 3,000,000 shares (or 150,000 shares) will be eligible for vesting in accordance with
Section 3.3(a). Accordingly, 75,000 of these “performance vested” 

  
 4. 

 
common shares will be immediately vested and exercisable on the two (2) year anniversary of the Start Date, with the remaining 75,000 shares vesting quarterly over the next two
(2) years, subject to the Executive’s continued employment on each vesting date. 
 (d) In addition to the Option Awards
and the Anti-Dilution Grants described in Section 3(c), the Executive shall also be eligible to receive semi-annual grants on each six (6)-month anniversary of the Start Date until such time the Parent has raised an aggregate of
$200 million from any source (the “Equity Award Anti -Dilution Grants”). The Equity Award Anti-Dilution Grants shall each cover a number of shares equal to five percent (5%) of the net positive number of Parent common
shares underlying equity awards that were granted to individuals (other than the Executive) in the prior six (6)-month period less any such equity awards that were forfeited during such six (6)-month period, provided that the cumulative net number
of Parent common shares underlying equity grants issued since the Start Date (excluding the Option Awards and the Anti-Dilution Grants) compared to the number of such equity awards forfeited is positive at the time of measurement. The Equity Award
Anti-Dilution Grants will have an exercise price equal to the fair market value of Parent common stock on the applicable grant date and will be subject to a 4-year vesting period, with (i) twenty-five
percent (25%) of each Equity Award Anti-Dilution Grant vesting on the one-year anniversary of the grant date thereof and (ii) the balance of each Equity Award Anti-Dilution Grant vesting in a series of
twelve (12) successive equal quarterly installments measured from the first anniversary of the grant date thereof, provided the Executive is employed by the Company on each such vesting date. The Equity Award Anti-Dilution Grant will be
governed by the Plan and other documents issued in connection with the grants and will expire and cease to be exercisable on the earlier of (i) ten (10) year anniversary of the grant date thereof or (ii) the date that the applicable Equity
Award Anti-Dilution Grant (or portion thereof) is cancelled or forfeited prior to the exercise thereof, subject to the terms of the Plan and the applicable award agreement. For the avoidance of doubt, (i) the Executive shall not be eligible to
receive any additional Equity Award Anti-Dilution Grants from and after the point in which the Parent has raised an aggregate of $200 million from any source and (ii) no Equity Award Anti-Dilution Grants shall be made if, on the date such
grant would otherwise be made, the cumulative net number of equity grants issued under the Plan, taking into account all equity awards issued from the Start Date (excluding the Option Awards and the Anti-Dilution Grants) compared to the number of
such equity awards forfeited is negative. Upon a Change of Control (as defined in the Plan), any unvested portion of the Equity Award Anti-Dilution Grants shall immediately vest in full. 

3.4 Benefits and Insurance. The Executive shall, in accordance with Company policy and the terms of the applicable plan
documents, be eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to similarly situated Company executives (including, but not limited to, being named as an officer for
purposes of the Company’s Directors & Officers insurance policy). The Company reserves the right to modify, add or eliminate benefits from time to time. The Executive shall be entitled to vacation each year, in addition to sick leave
and observed holidays in accordance with the policies and practices of the Company. Vacation may be taken at such times and intervals as the Executive shall determine, subject to the business needs of the Company. 

3.5 Attorney’s Fees. The Executive shall be reimbursed by the Company for the reasonable attorney’s fees incurred by
the Executive in negotiating this Agreement, up to twenty five thousand dollars ($25,000), upon the Company’s receipt of such appropriate documentation thereof as the Company may require. 

  
 5. 

 3.6 Expense Reimbursements. The Company will reimburse the Executive for all
reasonable business expenses that the Executive incurs in conducting his duties hereunder, pursuant to the Company’s usual expense reimbursement policies. Reimbursement will be made as soon as practicable following receipt from the Executive of
reasonable documentation supporting said expenses. 
 4. PROPRIETARY INFORMATION
OBLIGATIONS. 
 As a condition of employment, the Executive agrees to execute and abide by the Company’s Employee Non-Disclosure and Inventions Assignment Agreement (“NDA”). 
 5.
TERMINATION OF EMPLOYMENT. 
 5.1 Termination Without Cause Or Resignation For
Good Reason. If the Executive’s employment with the Company is terminated without Cause or the Executive resigns for Good Reason (as defined below), then the Company shall pay the Executive any earned but unpaid Base Salary and unused
vacation accrued (if applicable) through the date of termination, at the rates then in effect, less standard deductions and withholdings. In addition, if the Executive furnishes to the Company an executed waiver and release of claims in the form
attached hereto as Exhibit A (the “Release”) and if the Executive allows the Release to become effective in accordance with its terms, then the Executive shall receive the following benefits: 

(a) The Company shall pay the Executive severance in an amount equal to one times (1x) the sum of the (i) Executive’s then
current Base Salary and (ii) the Executive’s target Annual Performance Bonus opportunity in respect of the calendar year in which the termination of employment occurs. Said amount shall be paid to the Executive in a single lump sum within
five (5) days following the Release becoming effective and irrevocable and will be subject to required withholding. Notwithstanding the foregoing, if such severance amounts are being paid upon a termination under this Section 5.1 within
twenty-four (24) months following the consummation of a Change of Control, the multiplier set forth in this Section 5.1(a) shall be two times (2x), rather than one times (1x). 

(b) If the Executive is eligible for and timely elects COBRA continuation coverage under the federal COBRA law or applicable state law
(collectively, “COBRA”), the Company will reimburse COBRA premiums for the first thirty-six (36) months of COBRA coverage; provided, however, that if the Executive
ceases to be eligible for COBRA under applicable law or becomes eligible to enroll in the group health insurance plan of another employer, the Executive shall immediately notify the Company and the Company’s obligation to provide the COBRA
premium benefits shall immediately cease. Further, notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without potentially incurring financial costs or
penalties under applicable law, then in lieu of paying COBRA premiums on the Executive’s behalf, the Company will pay the Executive on a monthly basis a fully taxable cash payment equal to the COBRA premium for that month, subject to applicable
tax withholding. 

  
 6. 

 (c) The Option Awards, including the Anti-Dilution Options, but only to the extent
the share raising “performance condition” under the Anti-Dilution Options has previously been satisfied, and any other equity incentive awards granted to the Executive that are subject solely to time-based vesting conditions shall all vest
in full upon such termination. 
 5.2 Other Termination. If the Executive resigns his employment at any time without Good
Reason or the Executive’s employment is terminated by the Company at any time for Cause or due to death or Disability (as defined below), the Company shall pay the Executive (or his estate) any Base Salary and any unused vacation accrued (if
applicable) through the date of such resignation or termination, at the rates then in effect, less standard deductions and withholdings. In addition, in the event of a termination due to death or Disability, the Executive (or his estate) will be
paid an amount equal to the Executive’s target Annual Performance Bonus amount for the year in which such termination occurs prorated to the date of such termination. The Company shall thereafter have no further obligations to the Executive,
except as may otherwise be required by law. 
 5.3 Definitions. For purposes of this Agreement, the following terms shall have
the following meanings: 
 (a) “Cause” shall mean the occurrence of any of the following, the
Executive’s: (i) conviction of any felony or any crime involving moral turpitude or dishonesty, (ii) participation in a fraud against the Company, (iii) willful and material breach of the Executive’s duties and obligations
under this Agreement or any other agreement between the Executive and the Company or its affiliates that has not been cured (if curable) within thirty (30) days after receiving written notice from the Board of such breach, (iv) intentional
and material damage to the Company’s property, or (v) violation of any law, rule or regulation (collectively, “Law”) relating in any way to the business or activities of the Company or its subsidiaries or
affiliates, or other Law that is violated during the course of the Executive’s performance of services hereunder that results in the Executive’s arrest, censure, or regulatory suspension or disqualification, including, without limitation,
the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335(a), or any similar legislation applicable in the United States or in any other country where the Company intends to develop its activities. 

(b) “Disability” shall mean the Executive’s inability to perform his duties and responsibilities
hereunder, with or without reasonable accommodation, due to any physical or mental illness or incapacity, which condition has continued for a period of 180 days (including weekends and holidays) in any consecutive
365-day period. 
 (c) “Good Reason” shall mean the occurrence of
any of the following events without the Executive’s consent: (i) a material reduction of the Executive’s Base Salary or target Annual Performance Bonus as initially set forth herein or as the same may be increased from time to time,
provided, however, that if such reduction occurs in connection with a Company-wide decrease in executive officer team compensation, such reduction shall not constitute Good Reason provided that it is a reduction of a proportionally
like amount or percentage affecting the entire executive team not to exceed 10%; (ii) material reduction in the Executive’s authority, duties or responsibilities, as compared to the Executive’s authority, duties or responsibilities
immediately prior to such reduction; or (iii) a change in the Executive’s principal location of employment, 

  
 7. 

 
resulting in an increase in the Executive’s one-way driving distance by more than fifty (50) miles from the Executive’s then current
principal residence on file with the Company; provided, however, any resignation by the Executive shall only be deemed for Good Reason pursuant to this definition if: (1) the Executive gives the Company written notice of the Executive’s
intent to terminate for Good Reason within ninety (90) days following the first occurrence of the condition(s) that he believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such
condition(s) within thirty (30) days following receipt of the written notice (the “Cure Period”); and (3) the Executive voluntarily terminates his employment within thirty (30) days following the end of the
Cure Period. 
 (d) A “Change of Control” means the occurrence, in a single transaction or in a series of
related transactions, of any one or more of the following events: 
 (i) A merger or consolidation in which the Company is a
constituent party (or a subsidiary of the Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation), other than a merger or consolidation in which the voting securities of the Company
outstanding immediately prior to such merger or consolidation continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of
the voting securities of the surviving entity outstanding immediately after such merger or consolidation; or 
 (ii) Any transaction
or series of related transactions in which an excess of fifty percent (50%) of the Company’s voting power is transferred, other than the sale by the Company of stock in transactions the primary purpose of which is to raise capital for the
Company’s operations and activities; or 
 (iii) A sale, lease, exclusive license or other disposition of all or substantially
all of the assets of the Company. 
 Notwithstanding the foregoing definition, the term Change of Control will not include (x) a sale of assets, merger
or other transaction effected exclusively for the purpose of changing the domicile of the Company or Parent, or (y) a liquidation or dissolution ancillary to or in connection with an assignment for the benefit of creditors, a bankruptcy
proceeding, appointment of receiver or similar proceeding or transaction. 
 5.4 “Release Date” shall mean
the date that is fifty-five (55) days following the date of the Executive’s termination. 
 5.5 Effect of
Termination. The Executive agrees that should his employment be terminated for any reason, he shall be deemed to have resigned from any and all positions with the Company. 

5.6 Section 409A Compliance. 

(a) It is intended that any benefits under this Agreement satisfy, to the greatest extent possible, the exemptions from the
application of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), provided under Treasury Regulations 

  
 8. 

 
Sections 1.409A-1(b)(4), and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible
as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Section 409A (including, without
limitation, for purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii)), the Executive’s right to receive any installment payments under this Agreement (whether severance payments, if any, or
otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. A termination of employment shall not be deemed to
have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning
of Section 409A and, for purposes of any such provision of this Agreement, references to a “resignation,” “termination,” “termination of employment” or like terms shall mean separation from service. Notwithstanding
any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of a separation from service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i), and if any payments or benefits
that the Executive becomes entitled to under this Agreement on account of such separation from service are deemed to be “deferred compensation,” then to the extent delayed commencement of any portion of such payments or benefits is
required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided prior to the earliest of (i) the expiration of the six-month period measured from the date of separation from service, (ii) the date of Executive’s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse
taxation. Upon the first business day following the expiration of such period, all payments deferred pursuant to this paragraph shall be paid in a lump sum, and any remaining payments due shall be paid as otherwise provided herein. No interest shall
be due on any amounts so deferred. 
 (b) With regard to any provision herein that provides for reimbursement of costs and expenses
or in-kind benefits, except as permitted by Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange
for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, and (iii) such payments shall be made on or before the last day of the Executive’s taxable year following the taxable year in which the expense
was incurred. The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Code Section 409A
but do not satisfy an exemption from, or the conditions of, Code Section 409A. 
 5.7 Section 280G. 

(a) If any payment or benefit (including payments and benefits pursuant to this Agreement) that the Executive would receive in
connection with a Change of Control or other transaction (the “Transaction”) from the Company or otherwise (“Transaction Payment”) would (i) constitute a “parachute payment” within the
meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”), then (I) in the event of the 

  
 9. 

 
consummation of a Transaction prior to the earlier of (x) the consummation of an initial public offering of the Company or the Parent (“IPO”) and (y) the 4th anniversary of the Start Date, the Company shall make payment to Executive of a Gross-Up Payment in accordance with the provisions of Exhibit B
attached to this Agreement and (II) in the event of the consummation of a Transaction on or after the IPO or the 4th anniversary of the Start Date, whichever is earlier, then the Company shall cause to be determined, before any amounts of the
Transaction Payment are paid to the Executive, which of the following two alternative forms of payment would result in the Executive’s receipt, on an after-tax basis, of the greater amount of the
Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to the Excise Tax: (1) payment in full of the entire amount of the Transaction Payment (a “Full Payment”), or
(2) payment of only a part of the Transaction Payment so that the Executive receives the largest payment possible without the imposition of the Excise Tax (a “Reduced Payment”). For purposes of determining whether to
make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account the value of all applicable federal, state and local income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net
of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is made, (x) the Executive shall have no rights to any additional payments and/or benefits
constituting the Transaction Payment, and (y) reduction in payments and/or benefits shall occur in the manner that results in the greatest economic benefit to the Executive as determined in this paragraph. If more than one method of reduction
will result in the same economic benefit, the portions of the Transaction Payment shall be reduced pro rata. 
 (b) Notwithstanding
the foregoing, in the event that no stock of the Company is readily tradeable on an established securities market or otherwise (within the meaning of Section 280G of the Code) at the time of the Change of Control of the Company, the Company
shall cause a vote of shareholders to be held to approve the portion of the Transaction Payments that equals or exceeds three times (3x) the Executive’s “base amount” (within the meaning of Section 280G of the Code) (the
“Excess Parachute Payments”) in accordance with Treas. Reg. §1.280G-1, and the Executive shall cooperate with such vote of shareholders, including the execution of any required
documentation subjecting the Executive’s entitlement to all Excess Parachute Payments to such shareholder vote. In the event that the Company does not cause a vote of shareholder to be held to approve all Excess Parachute Payments, the
provisions set forth in Section 5.7(a) of this Agreement shall apply. 
 (c) Unless the Executive and the Company otherwise
agree in writing, any determination required under this section shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon the
Executive and the Company for all purposes. For purposes of making the calculations required by this section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith
interpretations concerning the application of Sections 280G and 4999 of the Code. The Accountants shall provide detailed supporting calculations to the Company and the Executive as requested by the Company or the Executive. The Executive and the
Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this section. The Company shall bear all costs the Accountants may reasonably incur in
connection with any calculations contemplated by this section as well as any costs incurred by Executive with the Accountants for tax planning under Sections 280G and 4999 of the Code. 

  
 10. 

 6. ARBITRATION. 

Except as otherwise set forth below in connection with equitable remedies, any dispute, claim or controversy arising out of or relating to
this Agreement or the Executive’s employment with the Company (collectively, “Disputes”), including, without limitation, any dispute, claim or controversy concerning the validity, enforceability, breach or termination of
this Agreement, if not resolved by the parties, shall be finally settled by arbitration in accordance with the then-prevailing Employment Arbitration Rules and Procedures of JAMS, as modified herein (“Rules”). The requirement
to arbitrate covers all Disputes (other than disputes which by statute are not arbitrable) including, but not limited to, claims, demands or actions under the Age Discrimination in Employment Act (including Older Workers Benefit Protection Act);
Americans with Disabilities Act; Civil Rights Act of 1866; Civil Rights Act of 1991; Employee Retirement Income Security Act of 1974; Equal Pay Act; Family and Medical Leave Act of 1993; Title VII of the Civil Rights Act of 1964; Fair Labor
Standards Act; Fair Employment and Housing Act; and any other law, ordinance or regulation regarding discrimination or harassment or any terms or conditions of employment. There shall be one arbitrator who shall be jointly selected by the parties.
If the parties have not jointly agreed upon an arbitrator within twenty (20) calendar days of respondent’s receipt of claimant’s notice of intention to arbitrate, either party may request JAMS to furnish the parties with a list of
names from which the parties shall jointly select an arbitrator. If the parties have not agreed upon an arbitrator within ten (10) calendar days of the transmittal date of such list, then each party shall have an additional five
(5) calendar days in which to strike any names objected to, number the remaining names in order of preference, and return the list to JAMS, which shall then select an arbitrator in accordance with the Rules. The place of arbitration shall be
[Orange County], California. By agreeing to arbitration, the parties hereto do not intend to deprive any court of its jurisdiction to issue a pre-arbitral injunction, including, without limitation, with
respect to the NDA. The arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. §§ 1-16. Judgment upon the award of the arbitrator may be entered in any court of competent
jurisdiction. The arbitrator shall: (a) have authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a
written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based.
The Company shall pay all administrative fees of JAMS in excess of $435 (a typical filing fee in court) and the arbitrator’s fees and expenses. Each party shall bear its or his own costs and expenses (including attorney’s fees) in any such
arbitration and the arbitrator shall have no power to award costs and attorney’s fees except as provided by statute or by separate written agreement between the parties. In the event any portion of this arbitration provision is found
unenforceable by a court of competent jurisdiction, such portion shall become null and void leaving the remainder of this arbitration provision in full force and effect. The parties agree that all information regarding the arbitration, including any
settlement thereof, shall not be disclosed by the parties hereto, except as otherwise required by applicable law. 

  
 11. 

 7. GENERAL PROVISIONS. 

7.1 Representations and Warranties. The Executive represents and warrants that the Executive is not restricted or prohibited,
contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that the Executive’s execution and performance of this Agreement will not violate or breach any other agreements
between the Executive and any other person or entity. In addition, the Executive represents and warrants that the Executive is not debarred and has not received notice of any action or threat with respect to debarment under the provisions of the
Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335(a) or any similar legislation applicable in the United States or in any other country where the Company intends to develop its activities. The Executive understands and agrees that this
Agreement is contingent on the Executive’s submission of satisfactory proof of identity and legal authorization to work in the United States, as well as verification of auditor independence. 

7.2 Advertising Waiver. The Executive agrees to permit the Company, and persons or other organizations authorized by the
Company, to use, publish and distribute advertising or sales promotional literature concerning the products and/or services of the Company in which the Executive’s name and/or pictures of the Executive appear. The Executive hereby waives and
releases any claim or right the Executive may otherwise have arising out of such use, publication or distribution. 
 7.3
Miscellaneous. This Agreement, along with the NDA and any applicable equity awards that have been granted, constitutes the complete, final and exclusive embodiment of the entire agreement between the Executive and the Company with regard to
its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may not
be modified or amended except in a writing signed by both the Executive and a duly authorized officer or member of the Board. This Agreement will bind the heirs, personal representatives, successors and assigns of both the Executive and the Company,
and inure to the benefit of both the Executive and the Company, and to his and its heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not
affect any other provision of this Agreement and the provision in question will be modified so as to be rendered enforceable. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of
the State of California as applied to contracts made and to be performed entirely within California. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement shall be in
writing and shall not be deemed to be a waiver of any successive breach. This Agreement may be executed in counterparts and facsimile signatures will suffice as original signatures. 

  
 12. 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the day and year first written above. 
  

					
	UROVANT SCIENCES, INC.
		
	 By:
	 	 /s/ Matthew Gline

		 	    Name: Matthew Gline
		 	    Title: Chief Financial Officer

  

	
	ACCEPTED AND AGREED:
	
	 /s/ Keith Katkin

	 KEITH KATKIN

 [Signature Page to K. Katkin Employment Agreement] 

 EXHIBIT A 

Form Of Release 

Reference is hereby made to the employment agreement, dated as of September 14, 2017 between Urovant Sciences Inc. (the
“Company”) and Keith Katkin (the “Executive”) (the “Employment Agreement”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Employment
Agreement. 
 WHEREAS, pursuant to the Employment Agreement, as a condition to the right to receive the
severance payments in accordance with the terms of the Employment Agreement (the “Separation Benefits”) in the event that the Executive’s employment is terminated without Cause or the Executive resigns for Good Reason,
the Executive must, among other things, sign, return and not revoke this general release of claims (this “General Release”); and 

WHEREAS, [the Company has terminated the Executive’s employment without Cause] [the Executive has
resigned for Good Reason], effective , 20     (the “Separation Date”). 
 NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants and agreements contained herein and in the Employment Agreement, and for other good and valuable consideration, the sufficiency and receipt of
which is hereby acknowledged, the Executive and the Company hereby agree as follows: 
 1. Separation Benefits/Consideration. Subject
to the Executive signing and returning this General Release and this General Release becoming effective and irrevocable within the time periods set forth below, Executive will have the right to receive the Separation Benefits in accordance with the
terms of the Employment Agreement. The Executive agrees that (i) he would not have any right to receive the Separation Benefits but for his execution (and non-revocation) of this General Release, and
(ii) the Separation Benefits are in full satisfaction of and in fact exceed all amounts and benefits to which the Executive may be eligible to receive arising out of or related to his employment if this General Release does not become effective
and irrevocable within the time periods set forth below. 
 2. General Release. (a) In consideration for the right to receive
the Separation Benefits and the mutual promises contained in the Employment Agreement and in this General Release, the Executive (on behalf of himself or herself and his heirs, administrators, representatives, executors, successors and assigns)
hereby knowingly and voluntarily releases and discharges, to the fullest extent permitted by law, the Company and its predecessors, successors and assigns, its and their direct or indirect parents, subsidiaries and affiliated entities, and, with
respect to each and all of the foregoing entities (including the Company), all of its and their respective present and former officers, directors, employees, agents, attorneys, members, owners, shareholders, partners, members, representatives,
trustees, employee benefit plans and administrators or fiduciaries of such plans (all of the foregoing, including the Company, collectively referred to as “Released Parties”), each individually and in their representative
capacities, of and from any and all actions, agreements, claims, damages, expenses (including attorney’s fees and costs), judgments, liabilities, obligations or suits of any kind whatsoever, in law, equity or otherwise, in any jurisdiction,
whether known or unknown, suspected or claimed, 

  
 1. 

 
specifically mentioned herein or not, which the Executive had, has or may have against any of the Released Parties by reason of any actual or alleged act, event, occurrence, omission, practice or
other matter whatsoever from the beginning of time up to and including the date that the Executive signs this General Release (collectively, “Claims”), specifically including but not limited to Claims arising out of or in any
way relating to: 
  

	 	•	 	 the Executive’s services as an employee, officer or director of the Company and/or its predecessors,
successors and assigns, and its and their direct or indirect parents, subsidiaries and affiliated entities; 

  

	 	•	 	 the Employment Agreement and the termination thereof, any other employment agreement and any compensation,
benefits and/or equity interests of any kind in connection with the Executive’s employment; 

  

	 	•	 	 any common law, public policy, company policy, contract (whether oral or written, express or implied) or tort law
having any bearing whatsoever on the terms and conditions of the Executive’s employment; 

  

	 	•	 	 any federal, state or local law, ordinance or regulation including, but not limited to, the following (each as
amended, if applicable): Age Discrimination in Employment Act (including Older Workers Benefit Protection Act); Americans with Disabilities Act; Civil Rights Act of 1866; Civil Rights Act of 1991; Employee Retirement Income Security Act of 1974
(except as to any vested benefits under the Company’s ERISA-covered employee benefit plans, if any); Equal Pay Act; Family and Medical Leave Act of 1993; National Labor Relations Act; Title VII of the Civil Rights Act of 1964; Worker Adjustment
and Retraining Notification Act; any provision of the California Labor, Civil or Government Code; IWC Wage Orders; and any other law, ordinance or regulation regarding discrimination or harassment or any terms or conditions of employment.

 The Executive agrees that he has entered into this General Release as a compromise and in full and final settlement of
all Claims, if any, that the Executive has, had or may have against any and all of the Released Parties up to and including the date that the Executive signs this General Release. The Executive also agrees that, although he may hereafter discover
Claims presently unknown or unsuspected, or new or additional facts from those which he now knows or believes to be true, the Executive intends to provide a complete waiver of all Claims based on any facts and circumstances, whether known or
unknown, up to and including the date that the Executive signs this General Release. In this regard, the Executive further agrees that all of his rights under Section 1542 of the Civil Code of the State of California (and any equivalent
provision of any statute of the United States or any other state or jurisdiction) are hereby waived. Section 1542 provides as follows: 

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing
the release, which if known by him or her must have materially affected his or her settlement with the debtor. 

  
 2. 

 (b) Notwithstanding the foregoing, “Claims” does not include
(i) claims to enforce the terms of this General Release, (ii) claims that arise after the date that Executive signs this General Release (other than any claims relating to continuing or future effects of alleged past discrimination),
and/or (iii) claims that cannot be released by a private settlement agreement (such as statutory claims for worker’s compensation/disability insurance benefits and unemployment insurance benefits), the rights to all of which are hereby
specifically reserved. 
 (c) The Executive represents that he has not assigned or transferred his rights with respect to any Claims and
that he has not filed, directly or indirectly, any legal proceeding against any Released Parties regarding any Claims. If the Executive commences (or commenced) or participates in any action or proceeding (including as a member of a class of
persons) relating to any Claims, this General Release shall be a complete defense in such action or proceeding with respect to such Claims and, to the maximum extent permitted by law, the Executive (and his heirs, administrators, executors,
representatives, successors and assigns) will have no right to obtain or receive, and will not seek or accept, any damages, settlement or relief of any kind (including attorneys’ fees and costs) in connection with such Claims. 

3. Covenants of the Executive. The Executive acknowledges and agree that he continues to be bound by the terms and covenants set forth
in the Employee Non-Disclosure and Inventions Assignment Agreement between the Executive and the Company (the “NDA”), which will continue to remain in full force and effect for the
periods set forth therein. The Executive also agrees that any obligations of his or hers pursuant to provisions of the Company’s employee handbook and/or any other Company policies or agreements relating to confidential or proprietary
information and intellectual property (the “Confidentiality/IP Policies”) will continue to remain in full force and effect in accordance with their terms. 

4. Entire Agreement; Severability. (a) Upon its effectiveness, this General Release (the NDA and the Confidentiality/IP Policies,
all of which are incorporated herein by reference) contains the entire agreement and understanding of the parties relating to the subject matter hereof and supersedes and replaces all prior and contemporaneous agreements, representations and
understandings (whether oral or written) regarding the subject matter hereof. The Executive acknowledges that no promises or representations, oral or written, have been made relating to the subject matter hereof, and that the Executive has not
relied on any other promises or representations in signing this General Release. This General Release may be modified only in a document signed by the Executive and the Company and referring specifically hereto, and no handwritten changes to this
General Release will be binding unless initialed by the Executive and the Company. 
 (b) If any provision of this General Release is held
to be unenforceable for any reason, the parties intend that such portion be modified to make it enforceable to the maximum extent permitted by law. If any such provision (other than the general release provisions contained in Section 2(a)
hereof) cannot be modified to be enforceable, such provision shall become null and void leaving the remainder of this General Release in full force and effect. 

5. Governing Law. This General Release shall be governed by and construed and enforced in accordance with the laws of the State of
California, without regard to its rules regarding conflict of laws. 

  
 3. 

 6. Miscellaneous; Breach. (a) This General Release shall be binding upon and
inure to the benefit of (i) the Released Parties, including the successors and assigns of the Released Parties, all of which are intended third-party beneficiaries, and (ii) the Executive and his heirs, executors, administrators,
representatives, successors and assigns (but, in any event, this General Release is not assignable by the Executive and any purported assignment by the Executive shall be null and void). This General Release is not an admission of liability or
wrongdoing by the Executive or any of the Released Parties, and such wrongdoing or liability is expressly denied. This General Release may be executed in counterparts, each of which will be deemed an original, but all of which will be deemed one and
the same instrument. Any facsimile or pdf copy of any party’s executed counterpart of this General Release will be deemed to be an executed original thereof. All payments and benefits provided hereunder shall be subject to the withholding of
all applicable taxes and deductions required by any applicable law. 
 (b) In the event of a breach (or threatened breach) by the Executive,
the Executive agrees that the Released Parties (i) would have no adequate remedy at law and would be irreparably harmed, (ii) shall therefore be entitled to injunctive relief (without proving actual damages or posting a bond or other
security), both preliminary and permanent, enjoining such breach (or threatened breach) and (iii) in the event of a breach of the NDA or the Confidentiality/IP Policies, shall not be required to make any further Separation Benefits to the
Executive, for the period starting immediately following such breach and the Executive shall be required to return any Separation Benefits made from the date such breach is determined to have occurred (but, in any event, the Executive shall continue
to be subject to and bound by the terms of this General Release and also the NDA and the Confidentiality/IP Policies in accordance with the terms stated therein). Such remedies shall be in addition to all other remedies available at law or in
equity. 
 7. Review/Revocation. The Executive acknowledges that he has been given at least 21 days from his receipt of this General
Release to consider its meaning and effect and to determine whether he wishes to sign it. If the Executive signs this General Release before the 21 days are over, the Executive agrees that he is voluntarily waiving the rest of the 21 days without
any encouragement or pressure from any of the Released Parties to do so. The Executive also agrees that any modifications to this General Release, whether material or immaterial, will not restart the 21-day
period. UPON ITS EFFECTIVENESS, THIS GENERAL RELEASE WILL BE A LEGAL AND BINDING CONTRACT. AS SUCH, THE EXECUTIVE IS AND HAS BEEN ADVISED AND ENCOURAGED TO CONSULT WITH AN ATTORNEY OF HIS CHOOSING (AT HIS OWN EXPENSE) BEFORE SIGNING THIS GENERAL
RELEASE. Once the Executive signs this General Release, he may change his mind and revoke his acceptance of this General Release but only within seven (7) days after the date that he signed it. In order to do so, any revocation must be in
writing and sent to                      by overnight mail, signature required, within the seven (7) days after the date that the Executive
signed this General Release. This General Release shall not become effective until after the expiration of the revocation period described in this paragraph. If the Executive does not revoke this General Release within the seven (7) day period,
this General Release will become effective, enforceable and irrevocable on the eighth (8th) day after the date on which the Executive signed this General Release. 

*        *        * 

  
 4. 

 BY SIGNING THIS GENERAL RELEASE, THE EXECUTIVE AGREES THAT HE HAS READ IT IN ITS ENTIRETY
AND UNDERSTANDS ALL OF ITS TERMS AND EFFECTS, INCLUDING THAT HE IS PROVIDING A COMPLETE RELEASE OF ALL “CLAIMS,” WHETHER KNOWN OR UNKNOWN, UP TO AND INCLUDING THE DATE THAT HE SIGNS THIS GENERAL RELEASE. THE EXECUTIVE
ACKNOWLEDGES THAT HE HAS HAD AMPLE TIME TO REVIEW THIS GENERAL RELEASE AND TO CONSULT WITH AN ATTORNEY (IF HE SO CHOSE) AND THAT HE IS SIGNING IT KNOWINGLY AND VOLUNTARILY. THE EXECUTIVE ALSO ACKNOWLEDGES THAT THE “SEPARATION
BENEFITS” ARE GREATER THAN ANY PAYMENTS OR BENEFITS TO WHICH THE EXECUTIVE MAY OTHERWISE BE ENTITLED IF HE DID NOT EXECUTE THIS GENERAL RELEASE. 

For the right to receive the Separation Benefits in accordance with the terms of this General Release and the mutual promises contained in the
Employment Agreement and in this General Release, the Executive must (i) sign and date this General Release where indicated below, (ii) return the signed General Release to
                    , on or before
                    , 201     and (iii) not revoke this General Release within the time period set forth in Section 7
above. If the Executive does not sign and return this General Release on or before such date (or if the Executive revokes it as set forth above), the Executive will not be eligible to receive the Separation Benefits; however, in any event, the
termination of the Executive’s employment will still be effective as of the Separation Date. 
 IN
WITNESS WHEREOF, and intending to be legally bound hereby, the parties hereto have executed this General Release as of the dates and years written below. 

 

									
	UROVANT SCIENCES INC.:	  		 	EXECUTIVE:
				
	By:	 	  
	  		 	  

		 	    Name:	  		 	Executive	  	
		 	    Title:	  		 		  	
				
	Date:	  		 	Date:	  	

  
 5. 

 EXHIBIT B 

(a) Except as set forth below, in the event it shall be determined that any Payment would be subject to the Excise Tax, then the Executive
shall be entitled to receive from the Company an additional payment (the “Gross-Up Payment”) in an amount such that after payment by Executive of all taxes (including any interest or
penalties imposed with respect to such taxes), including, without limitation, any income taxes (and any interest and penalties imposed with respect thereto) and Excise Tax imposed upon the Gross-Up Payment,
but excluding any income taxes and penalties imposed pursuant to Section 409A, the Executive retains an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments. For the avoidance
of doubt, the Company’s obligation to make Gross-Up Payments under this Exhibit B shall not be conditioned upon the Executive’s termination of employment. 

(b) All fees and expenses of the Accountants shall be borne solely by the Company. As a result of the uncertainty in the application of
Section 4999 of the Code at the time of the initial determination by the Accountants hereunder, it is possible that Gross-Up Payments that will not have been made by the Company should have been made (the
“Underpayment”) or Gross-Up Payments that have been made by the Company should not have been made (“Overpayment”), consistent with the calculations required to
be made hereunder. In the event that the Company exhausts its remedies set forth below and the Executive thereafter is required to make a payment of any Excise Tax, the Accountants shall determine the amount of the Underpayment or Overpayment, as
applicable, that has occurred and any such Underpayment shall be promptly paid by the Company to or for Executive’s benefit and any such Overpayment shall be promptly paid by the Executive to the Company, as applicable. 

(c) Any Gross-Up Payment, as determined by the Accountants, shall be paid by the Company to Executive
within ten (10) days of the receipt of the Accountants’ determination; provided that, the Gross-Up Payment shall in all events be paid no later than the end of Executive’s taxable year next
following Executive’s taxable year in which the Excise Tax (and any income or other related taxes or interest or penalties thereon) on a Payment are remitted to the Internal Revenue Service or any other applicable taxing authority. 

(d) To the extent requested by the Company, Executive shall cooperate with the Company in good faith in valuing, and the Accountants shall
take into account the value of, services provided or to be provided by Executive (including without limitation, Executive agreeing to refrain from performing services pursuant to a covenant not to compete or similar covenant) before, on or after the
date of a change in ownership or control of the Company (within the meaning of Q&A-2(b) of Section 280G of the Code), such that payments in respect of such services (or refraining from performing such
services) may be considered reasonable compensation within the meaning of Q&A-9 and Q&A-40 to Q&A-44 of
Section 280G of the Code and/or exempt from the definition of the term “parachute payment” within the meaning of Q&A-2(a) of Section 280G of the Code in accordance with Q&A-5(a) of Section 280G of the Code.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]